Abbott Laboratories (ABT)
After hours: 06:42PM EDT
| Previous close | 125.05 |
| Open | 125.51 |
| Bid | 126.72 x 800 |
| Ask | 126.68 x 1200 |
| Day's range | 124.88 - 126.84 |
| 52-week range | 103.13 - 129.70 |
| Volume | 4,874,988 |
| Avg. volume | 4,665,938 |
| Market cap | 224.652B |
| Beta (5Y monthly) | 0.67 |
| PE ratio (TTM) | 31.44 |
| EPS (TTM) | 4.03 |
| Earnings date | 20 Oct 2021 |
| Forward dividend & yield | 1.80 (1.44%) |
| Ex-dividend date | 14 Oct 2021 |
| 1y target est | 137.05 |
- Motley Fool
3 Things Investors Should Love About Abbott's Q3 Results
Abbott Laboratories (NYSE: ABT) has given investors plenty to like through the years. Abbott provided its third-quarter update before the market opened on Wednesday. Here are three things that investors should love about the healthcare-giant's Q3 results.
- Motley Fool
Why Abbott Laboratories Shot Higher Today
Abbott Laboratories (NYSE: ABT) easily surmounted Hump Day, rising by 3.4% and trouncing the S&P 500 index's gain as it did so. For the quarter, Abbott posted year-over-year sales growth of 23%, as its top line landed at $10.9 billion. Collectively, prognosticators tracking the healthcare company estimated that it would earn a bit more than $9.4 billion on the top line and post an adjusted net profit of $0.93.
- Motley Fool
Abbott Laboratories (ABT) Q3 2021 Earnings Call Transcript
With the exception of any participants' questions asked during the question-and-answer session, the entire call, including the question-and-answer session, is material copyrighted by Abbott. It cannot be recorded or rebroadcast without Abbott's expressed written permission. With me today are Robert Ford, President and Chief Executive Officer; and Bob Funck, Executive Vice President, Finance and Chief Financial Officer.
